GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nabriva Therapeutics NBRVF · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Nabriva Therapeutics — daily NBRVF Delayed
Market value
$323
Last close × shares
Volume
780
Shares, 30 Oct 2026

About Nabriva Therapeutics

Its shares trade under the ticker NBRVF. It has been listed since 18 September 2015. In the fiscal year to 31 December 2022, it reported revenue of $35.7m and a net loss of $57.2m. At that date it held total assets of $31.8m and shareholders' equity of $3.3m.

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.

Figures and description from our data supplier, not checked against the company's own report.

More about Nabriva Therapeutics →

Latest on Nabriva Therapeutics

Our reporting

We have not reported on Nabriva Therapeutics yet.

Next results

13 Nov 2026

Due on 13 Nov 2026. Analysts expect earnings of -16.75 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Nabriva Therapeutics's ticker?

Nabriva Therapeutics trades as NBRVF on its US listing, under ISIN IE000OZRGNV6.

What was Nabriva Therapeutics's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

When does Nabriva Therapeutics next report results?

Results are expected on 13 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.